French Health Agency Backs Nicotine Caps, Citing 22nd Century's Tech as Only Commercial Path
XXII sits 21% above its 52-week low of $1.15 on elevated volume (2.3× avg).
Summary
France's ANSES recommends a maximum nicotine limit for all combustible tobacco, explicitly naming 22nd Century's reduced-nicotine tobacco as the only commercially available production path. The company has expanded its platform to include non-GMO tobacco, removing a key regulatory barrier for EU adoption. This follows a difficult year: Q2 revenue fell 30% to $2.9M with going concern doubts, and the stock trades near $1.39 after a June reverse split. The French market alone is estimated at over €20B annually, with a sustainable legal market of €8-13B post-regulation. EU legislative proposals are expected before end of 2026, creating a potential multi-billion-euro opportunity if the company can scale supply.
At the time of this announcement, XXII was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $949.6K. The 52-week trading range was $1.15 to $646.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.